Biologically Focused Therapy of Treatment-Refractory MDS Patients

Not Recruiting

Trial ID: NCT05245032


This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.

Official Title

Biologically Focused Therapy of Treatment Refractory MDS Patients

Stanford Investigator(s)

Peter Greenberg
Peter Greenberg

Professor of Medicine (Hematology), Emeritus


Inclusion Criteria:

* Provide informed consent;
* Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN with \>= 5% blasts in the bone marrow or peripheral blood, including chronic myelomonocytic leukemia (CMML) 1 and 2 by WHO classification
* Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating agent therapy
* Cytogenetics reported

Exclusion Criteria:

* Hypoplastic MDS
* Patients without adequate marrow samples for ex vivo analysis

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jack Taw

New Trial Alerts